Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics Review

  

Authors:	Rahbar, K.; Bodei, L.; Morris, M. J.
Review Title:	Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics
Abstract:	Prostate-specific membrane antigen (PSMA) is of considerable interest as a target for diagnostics and therapy of prostate cancer patients. PSMA-targeted imaging has demonstrable value in guiding the management of the clinical evolution of prostatic cancer. The use of PSMA-targeted therapy using 177Lu-labeled PSMA-617 is similarly effective and is progressing toward approval. The phase III VISION trial represents the largest well-designed and executed study of a theranostic pair. This article provides an overview of the phase III trial and delineates the different study arms and their implications in the assessment of efficacy. The VISION (phase III) trial will provide data of critical value to the field of theranostics and especially the field of prostatic cancer management. COPYRIGHT © 2019 by the Society of Nuclear Medicine and Molecular Imaging.
Keywords:	controlled study; unclassified drug; cancer radiotherapy; prospective study; randomized controlled trial; clinical assessment; cancer therapy; prostate cancer; open study; clinical effectiveness; phase 3 clinical trial; theranostics; castration resistant prostate cancer; futurology; radioligand; human; male; priority journal; article; theranostic nanomedicine; psma-targeted therapy; prostate specific membrane antigen 11 ga 68; prostate specific membrane antigen 617 lu 177
Journal Title:	Journal of Nuclear Medicine
Volume:	60
Issue:	11
ISSN:	0161-5505
Publisher:	Society of Nuclear Medicine
Date Published:	2019-11-01
Start Page:	1504
End Page:	1506
Language:	English
DOI:	10.2967/jnumed.119.234054
PUBMED:	31451487
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074445573&doi=10.2967%2fjnumed.119.234054&partnerID=40&md5=60adf123ca29f17de6f16df865043fe3
Notes:	Article -- Export Date: 2 December 2019 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/156693